ClinChoice Advantages

ClinChoice has more than 29 years of operating history worldwide, with 17 years of experience in China, serving both local and global clients for the development of innovative drugs, biologicals and medical devices.

As a global company with operations across Asia, Europe, North America, Southeast Asia, Australia and New Zealand, ClinChoice provides a broad portfolio of clinical development services that enable global pharma and biotech companies to advance discoveries and deliver ground-breaking treatments to patients. Our wide network of clinical experts ensures global consistency and high standards that meet ICH-GCP guidelines. Our clinical development team in China works very closely with our Site Start Up (SSU) and Site Management Organization (SMO) teams to ensure studies can be initiated as quickly as possible.

Global Presence

• Over 29 years of experience to support with MNC and emerging biopharma worldwide
• World-class team with over 4,000 well-educated and high-caliber clinical research professionals across 80+ cities and 20+ countries around the world
• Managed by seasoned industry veterans from world leading CRO such as Quintiles, Covance, PPD and MNC Pharma

China Network

• Over 17 years operating history in China with  1,100+ studies from Ph1 to Ph4.
• ~1,800+ China clinical operation and biometrics team
• Robust China platform with access to 300 GCP-standard clinical sites
• Solid relationships with 1,000+ principal investigators in China

Global Quality Standards

• Strictly adhere to GCP and ICH standards, advised by world-class experts
• SOP system audited by 50+ global pharma clients with 100% pass rate of onsite inspection by CFDA, FDA & EMA
• Medidata and Oracle accredited local CRO, CDISC (Clinical Data Interchange Standards Consortium) Gold Member

Full-service & Innovation

• Full-service capability established in China, US and around the world to serve both local, regional and global customers
• Focus on emerging biotech and MedTech companies, especially the development of innovative drugs, biologics, new therapeutics (cell therapy, gene therapy etc.) and medical devices

ClinChoice China Team Overview（as of June 25, 2024）

  • Full Team
    • 1,800 employees in China
  • Clinical Operations Core Team
    • 80+ experienced project managers (PM)
    • 60+ professional site start-up managers and specialists (SSU)
    • 260+ well-trained clinical research associates (CRA)
    • 65+ clinical trial associates (CTA)

ClinChoice China Study Experience

  • 1,200+ clinical studies in China
  • 500+ oncology studies, 29.9% solid tumour studies
  • 770+ non-oncology studies
  • 68% early phase and pivotal studies
  • 1,300+ standalone business, with biometrics and regulatory dominant

ClinChoice China Clinical Operations Team Experience

  • A broad therapeutic area, 36% solid tumour studies
  • 100+ ongoing oncology studies, 20% lymphoma studies
  • Phase I-IV clinical studies and device studies, 75% early phase and pivotal studies

ClinChoice “Star Site” Program

  • ClinChoice has initiated a “Star Site” Program to establish a strategic partnership with celebrated clinical research units in China. By working closely with and taking advantages of each other, we are able to advance drug development programs rapidly and benefit the patients significantly.
  • 8 ClinChoice “Star Site” has been established across China as of Jun 2024 (2 in Beijing, 1 in Shandong, Zhejiang, Shanghai, Fujian, Guangzhou, Sichuan Provinces respectively).
  • Our Vision:
    • Streamline the process with high quality and speed
    • Share resources and utilize talents
    • Expand and diversify innovations
  • Our Uniqueness:
    • Seasoned industry professionals
    • Quality service and assurance
    • Recommendation of innovative studies
    • Access to integrated resources